Dosage for transition from Tyvaso Inhalation Solution: see full labeling. Risk of symptomatic hypotension in those with low systemic arterial pressure. Hepatic insufficiency; titrate slowly.

Liquidia Corporation (NASDAQ:LQDA) announced Thursday a lawsuit challenging the recent FDA decision to grant a three-year ...

United Therapeutics markets four products for pulmonary arterial hypertension (PAH) — Tyvaso, Orenitram, Adcirca and ...

TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD. Jul 19, 2013 9:39am ET Smallcappower.com Daily Investment Idea ...

Despite the unfavorable ruling for Liquidia, the regulatory exclusivity period for Tyvaso DPI is still set to expire on May 23, 2025. Additionally, United Therapeutics had filed a cross claim in ...